Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose

Authors


Correspondence

Professor David W. Haas MD, Microbiology & Immunology Vanderbilt University School of Medicine, Vanderbilt Health – One Hundred Oaks, 719 Thompson Lane, Suite 47183, Nashville, TN 37204, USA.

Tel.: +1 615 936 8594

Fax: +1 615 936 2644

E-mail: david.w.haas@vanderbilt.edu

Abstract

Aims

To determine pharmacokinetic and pharmacogenomic correlates of efavirenz central nervous system (CNS) side effects following a single dose.

Methods

Thirty-four healthy HIV-negative African Americans were administered a 600 mg dose of efavirenz. Blood samples for pharmacokinetics were drawn serially from 0 to 12 h post-dose. Neuropsychometric testing with drowsiness visual analogue scale, grooved pegboard and letter digit substitution tests was done the day prior to dosing and at 1, 2, 3, 4 and 6 h post-dose. Subjective CNS symptoms were assessed at 6 h post-dose. Composite CYP2B6 516/983 genotype was determined.

Results

Pharmacokinetic indices reflecting increased plasma efavirenz exposure were associated with slower non-dominant hand grooved pegboard task completion (Cmax, P1 h = 0.01, P2 h = 0.05, P3 h = 0.03, P4 h = 0.01; AUC, P1 h = 0.04; clearance P1 h = 0.05, P2 h = 0.02, P6 h = 0.01). In a repeated measures model analysis that adjusted timing of neuropsychometric testing for timing of peak drug concentration, clearance (P < 0.001), AUC(0.312 h) (P = 0.001) and Cmax (P = 0.008) were associated with non-dominant grooved pegboard test performance. CYP2B6 genotype trended to correlate with non-dominant hand grooved pegboard at 4 and 6 h (P = 0.07 and 0.06). Decreased drowsiness at 6 h was associated with higher Cmax (P = 0.02).

Conclusions

Following a single dose of efavirenz, an association between pharmacokinetics and neuropsychometric performance was discernable. A weaker association between genotype and neurocognitive test performance is likely mediated by effect of genotype on plasma clearance. Strategies that lower Cmax during initial dosing may decrease CNS side effects.

Ancillary